BACKGROUND-Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear.METHODS-We enrolled at-risk cisgender men and transgender persons in the Americas and Europe in the HVTN 704/HPTN 085 trial and at-risk women in sub-Saharan Africa in the HVTN 703/HPTN 081 trial. Participants were randomly assigned to receive, every 8 weeks, infusions of a bnAb (VRC01) at a dose of either 10 or 30 mg per kilogram (low-dose group and high-dose group, respectively) or placebo, for 10 infusions in total. HIV-1 testing was performed every 4 weeks. The VRC01 80% inhibitory concentration (IC 80 ) of acquired isolates was measured with the TZM-bl assay.
Candidate HIV-1 vaccines currently being evaluated in clinical trials are designed to elicit HIV-1-specific cellular immunity. Intracellular cytokine staining (ICS) assays allow sensitive, quantitative ex vivo assessments of antigen-specific T cells including immunophenotyping of responding cells and measurement of multiple effector functions. Additionally, the use of banked cryopreserved PBMC samples makes this assay attractive in the setting of large efficacy trials where it is less feasible to perform immunoassays on freshly isolated samples. Here we describe extensive studies to optimize and quantitatively validate the 8-color ICS assay for use in clinical trials of candidate vaccines, which includes measurement of viable IFN-gamma, IL-2, TNF-alpha and IL-4 producing CD4+ and CD8+ T cells. We show that omission of viability dye staining results in an over-estimate of the true antigen-specific T cell response by up to two-fold. After optimization, the 8-color assay was validated for specificity, precision, linearity, limit of quantitation and robustness. The assay has a lower quantitation limit generally below 0.04%, depending on the cytokine subset. Additionally, with appropriate gating, the 8-color assay gives comparable cytokine-positive responses to those observed with the conventional 4-color assay. In conclusion, we provide the first description of a quantitatively validated ICS assay, which permits quantitative and qualitative evaluation of vaccine-induced immunogenicity and analysis of immune correlates of protection.
BackgroundTenofovir gel has entered into clinical trials for use as a topical microbicide to prevent HIV-1 infection but has no published data regarding pre-clinical testing using in vitro and ex vivo models. To validate our findings with on-going clinical trial results, we evaluated topical tenofovir gel for safety and efficacy. We also modeled systemic application of tenofovir for efficacy.Methods and FindingsFormulation assessment of tenofovir gel included osmolality, viscosity, in vitro release, and permeability testing. Safety was evaluated by measuring the effect on the viability of vaginal flora, PBMCs, epithelial cells, and ectocervical and colorectal explant tissues. For efficacy testing, PBMCs were cultured with tenofovir or vehicle control gels and HIV-1 representing subtypes A, B, and C. Additionally, polarized ectocervical and colorectal explant cultures were treated apically with either gel. Tenofovir was added basolaterally to simulate systemic application. All tissues were challenged with HIV-1 applied apically. Infection was assessed by measuring p24 by ELISA on collected supernatants and immunohistochemistry for ectocervical explants. Formulation testing showed the tenofovir and vehicle control gels were >10 times isosmolar. Permeability through ectocervical tissue was variable but in all cases the receptor compartment drug concentration reached levels that inhibit HIV-1 infection in vitro. The gels were non-toxic toward vaginal flora, PBMCs, or epithelial cells. A transient reduction in epithelial monolayer integrity and epithelial fracture for ectocervical and colorectal explants was noted and likely due to the hyperosmolar nature of the formulation. Tenofovir gel prevented HIV-1 infection of PBMCs regardless of HIV-1 subtype. Topical and systemic tenofovir were effective at preventing HIV-1 infection of explant cultures.ConclusionsThese studies provide a mechanism for pre-clinical prediction of safety and efficacy of formulated microbicides. Tenofovir was effective against HIV-1 infection in our algorithm. These data support the use of tenofovir for pre-exposure prophylaxis.
BACKGROUND
A safe, effective vaccine is essential to end HIV. A canarypox/protein HIV
vaccine regimen showed modest efficacy at reducing infection in Thailand. An
analogous regimen using HIV-1 subtype C virus demonstrated potent humoral
and cellular responses in a Phase 1/2a trial and triggered a Phase 2b/3
double-blinded trial to assess the safety and efficacy of this regimen in
South Africa.
METHODS
We enrolled and randomized 5,404 healthy, HIV-uninfected 18-35-year olds at
14 sites to vaccine (2,704 participants) or placebo (2,700 participants)
between 26 October 2016 and 21 June 2019. The vaccine regimen consisted of
two ALVAC-HIV (vCP2438) (expressing HIV-1 subtype C
env,
clade B
gp41
,
gag
and
pro)
immunizations at months 0 and 1, with booster
immunizations of ALVAC-HIV plus bivalent subtype C gp120 protein/MF59
adjuvant at months 3, 6, 12 and 18. Efficacy was evaluated by HIV testing
every 3 months.
RESULTS
In January 2020, pre-specified non-efficacy criteria were met at an interim
analysis; further vaccinations were subsequently halted. The vaccines were
safe and well-tolerated in the study population (median age 24, 70%
female-sex-at-birth). Over the primary 24-month follow-up, there were 133
infections among placebo recipients and 138 among vaccinees (hazard ratio =
1.02; 95%CI, 0.81-1.30; P=0.84). Pre-specified subgroup analyses
demonstrated no difference in efficacy by sex or when restricting to
follow-up post-4
th
vaccination, and no difference amongst
female-sex-at-birth by age, BMI, prevalent STIs, behavioral risk score or
region.
CONCLUSIONS
The ALVAC/gp120 regimen did not prevent HIV infection in South Africans
despite prior evidence of immunogenicity.
ClinicalTrials.gov (NCT02968849)
Highlights d Meta-analysis of NHP studies administering a single bNAb before SHIV challenge d Serum neutralizing titers correlate strongly with protection against SHIV infection d ID50, ID80, and IIP all predict protection, with ID50 and ID80 stronger predictors d Substantial levels of neutralization might be needed for protection by a single bNAb
Recombinant viruses hold promise as vectors for vaccines to prevent infectious diseases with significant global health impacts. One of their major limitations is that preexisting anti-vector neutralizing antibodies can reduce T cell responses to the insert antigens; however, the impact of vector-specific cellular immunity on subsequent insert-specific T cell responses has not been assessed in humans. Here, we have identified and compared adenovirus-specific and HIV-specific T cell responses in subjects participating in two HIV-1 vaccine trials using a vaccine vectored by adenovirus serotype 5 (Ad5). Higher frequencies of pre-immunization adenovirus-specific CD4 + T cells were associated with substantially decreased magnitude of HIV-specific CD4 + T cell responses and decreased breadth of HIV-specific CD8 + T cell responses in vaccine recipients, independent of type-specific preexisting Ad5-specific neutralizing antibody titers. Further, epitopes recognized by adenovirus-specific T cells were commonly conserved across many adenovirus serotypes, suggesting that cross-reactivity of preexisting adenovirus-specific T cells can extend to adenovirus vectors derived from rare serotypes. These findings provide what we believe to be a new understanding of how preexisting viral immunity may impact the efficacy of vaccines under current evaluation for prevention of HIV, tuberculosis, and malaria.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.